About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

The official trailer for Shelter Me: The Cancer Pioneers” has just dropped, giving audiences a moving first look at the groundbreaking new documentary that follows the emotional and inspiring journey of dogs helping to pioneer cancer treatments that are saving human lives. The movie will stream through the PBS app and on PBS.org starting on Thursday, May 15.

The newest film in the Emmy Award-winning “Shelter Me” series, ‘The Cancer Pioneers’ brings viewers inside cutting-edge clinical trials where dogs with cancer are being treated with breakthrough immunotherapies, which are leading to treatments that are now extending and saving human lives, thanks to a revolutionary field of science called comparative oncology. The official trailer is available now at https://youtu.be/pFaockwrROM.

“This is one of the most powerful and consequential stories I’ve ever told,” said Steven Latham, “Shelter Me” series Creator and Producer. “Dogs are helping unlock the future of cancer treatment for people, and the results are incredibly promising.”

The documentary features leading scientists and veterinarians from world-renowned institutions including the National Institutes of Health, the National Cancer Institute, the University of Pennsylvania, the University of Illinois, the University of Wisconsin and Colorado State University. These scientists, researchers and veterinarians are working at the forefront of immunotherapy and cancer research, alongside beloved pets who are not only patients, but pioneers in their own right.

The official trailer captures the emotional stakes of the film: dogs that are beloved family members fighting cancer, dedicated and brave people, brilliant scientists and a future where hope comes on four legs.Shelter Me: The Cancer Pioneers is a powerful reminder of the unbreakable bond between humans and animals and how that relationship may hold the key to curing cancer.

“These therapies represent years of dedicated research and collaboration,” said Paul Romness, CEO of OS Therapies. “Veterinary oncology is now changing the trajectory of treatment for osteosarcoma patients. This film captures the real-world impact of that science.”

“Shelter Me: The Cancer Pioneers” is the latest installment in the acclaimed “Shelter Me series, which has aired nationally on PBS and inspired millions with its uplifting, animal-centered storytelling. The Shelter Me series is presented by Petco Love.

Screening opportunities and additional materials are available upon request.

To learn more about the “Shelter Me” series visit https://www.shelterme.tv/.

About “Shelter Me: The Cancer Pioneers”

“Shelter Me: The Cancer Pioneers" is about groundbreaking clinical trials for dogs with cancer which is leading to new treatments for people. Featuring leading scientists at the National Cancer Institute, National Institutes of Health and universities across the country. This field of science is called comparative oncology and dogs are leading the way for new immunotherapies. Dogs are amazing and are helping save our lives!

“Shelter Me” is an Emmy Award-winning PBS series that is produced by Steven Latham Productions and powered by Petco Love.

About OS Therapies

OS Therapies is excited to be partnering with Shelter Me. OS Therapies is a biotechnology company developing treatments for Osteosarcoma (OS) and other solid tumors in humans and canines. OST-HER2 is an immunotherapy leveraging the immune-stimulatory effects of bacteria to initiate a strong immune response targeting the HER2 protein. In Osteosarcoma, OST-HER2 has completed Phase I & Phase III trials in canines and recently a Phase IIb clinical trial in humans, these were highlighted in “Shelter Me: The Cancer Pioneers".

In humans, OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. In canines, OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of osteosarcoma.

In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.